Mary Eugenia Rinella

Mary Eugenia Rinella's AcademicInfluence.com Rankings

Philosophy

#7314

World Rank

#10508

Historical Rank

Logic

#4376

World Rank

#5659

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Mary Eugenia Rinella's Degrees

Doctorate Medicine University of Illinois Chicago

Why Is Mary Eugenia Rinella Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Mary Eugenia Rinella's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018) (3932)
Nonalcoholic fatty liver disease: a systematic review. (2015) (1735)
Mechanisms of NAFLD development and therapeutic strategies (2018) (1733)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019) (620)
The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. (2004) (387)
Nonalcoholic fatty liver disease (2015) (374)
Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet (2008) (370)
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (2018) (281)
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease (2020) (269)
Management of NAFLD: a stage-based approach (2016) (260)
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (2018) (254)
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis (2017) (248)
Body mass index as a predictor of hepatic steatosis in living liver donors (2001) (247)
Non-alcoholic fatty liver disease (2021) (239)
NAFLD 2020: The State of the Disease. (2020) (218)
Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. (2018) (203)
From NAFLD to MAFLD: Implications of a Premature Change in Terminology (2020) (203)
Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population‐based study (2015) (199)
Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events (2012) (188)
Systematic review with meta‐analysis: risk of hepatocellular carcinoma in non‐alcoholic steatohepatitis without cirrhosis compared to other liver diseases (2018) (174)
Advancing the global public health agenda for NAFLD: a consensus statement (2021) (167)
The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health (2016) (166)
Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. (2011) (157)
Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. (2015) (149)
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension. (2019) (148)
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension. (2019) (148)
The role of diet and nutrient composition in nonalcoholic Fatty liver disease. (2012) (146)
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial (2020) (145)
International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. (2018) (123)
Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD (2019) (115)
Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease (2016) (108)
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). (2022) (106)
Dual‐echo, chemical shift gradient‐echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation (2003) (104)
Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension. (2019) (87)
Regenerate: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. (2019) (83)
The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis (2011) (72)
Dysregulation of the unfolded protein response in db/db mice with diet‐induced steatohepatitis (2011) (71)
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. (2019) (69)
Controversies in the Diagnosis and Management of NAFLD and NASH. (2014) (68)
Practice patterns in NAFLD and NASH: real life differs from published guidelines (2016) (66)
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. (2019) (64)
NGM 282 for treatment of non-alcoholic steatohepatitis : a multicentre , randomised , double-blind , placebo-controlled , phase 2 trial (2018) (60)
NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD (2015) (57)
Non-alcoholic fatty liver disease: is bariatric surgery the answer? (2009) (57)
Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis (2015) (56)
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum (2019) (55)
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. (2019) (55)
GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH (2019) (54)
Pregnancy after liver transplantation. (2006) (54)
Longitudinal Association of Non‐Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study (2020) (51)
Screening for Non-Alcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the U.S. is Cost Effective: A Comprehensive Cost-Utility Analysis. (2020) (48)
Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices (2020) (48)
TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial. (2021) (47)
Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife (2017) (46)
Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis (2017) (42)
Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study (2017) (41)
A myriad of pathways to NASH. (2012) (37)
Body mass index trajectories in young adulthood predict non‐alcoholic fatty liver disease in middle age: The CARDIA cohort study (2018) (35)
NAFLD: Reporting Histologic Findings in Clinical Practice (2021) (34)
Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis (2016) (34)
Randomised clinical trial: a leucine‐metformin‐sildenafil combination (NS‐0200) vs placebo in patients with non‐alcoholic fatty liver disease (2018) (33)
Nonalcoholic fatty liver disease: Reporting histologic findings in clinical practice. (2020) (32)
Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study (2019) (32)
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. (2022) (30)
Transcriptional regulation of murine Slc22a1 (Oct1) by peroxisome proliferator agonist receptor-α and -γ (2005) (29)
Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis. (2019) (27)
The times they are a-changin' (for NAFLD as well). (2020) (26)
Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) (2017) (25)
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. (2021) (25)
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. (2021) (24)
JKB-121 in patients with nonalcoholic steatohepatitis: A phase 2 double blind randomized placebo control study (2018) (24)
Preparing for the NASH Epidemic: A Call to Action. (2021) (23)
Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. (2020) (23)
Non-alcoholic Fatty Liver Disease: Not Time for an Obituary Just Yet! (2020) (23)
Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. (2021) (23)
Preparing for the NASH epidemic: A call to action. (2021) (22)
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. (2021) (22)
STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus (2020) (21)
Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? (2011) (20)
Transcriptional regulation of murine Slc22a1 (Oct1) by peroxisome proliferator agonist receptor-alpha and -gamma. (2005) (20)
Hepatic overexpression of abcb11 promotes hypercholesterolemia and obesity in mice. (2011) (18)
Interpretation and management of hepatic abnormalities in pregnancy. (2013) (18)
Sex Hormone–Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife (2019) (17)
Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. (2019) (17)
Fundal variceal bleeding after correction of portal hypertension in patients with cirrhosis. (2003) (16)
AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. (2023) (15)
Real-World Burden of Nonalcoholic Steatohepatitis. (2020) (15)
NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients (2017) (14)
Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy‐proven nonalcoholic steatohepatitis (2019) (14)
563 Pentoxifylline Improves ALT and Histology in Patients with NASH, a Double Blind Placebo Controlled Trial (2009) (14)
A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension (2018) (14)
Randomized Controlled Trial of a Leucine‐Metformin‐Sildenafil Combination (NS‐0200) on Weight and Metabolic Parameters (2019) (14)
Liraglutide-induced autoimmune hepatitis. (2014) (14)
[Associating Serenoa repens, Urtica dioica and Pinus pinaster. Safety and efficacy in the treatment of lower urinary tract symptoms. Prospective study on 320 patients]. (2010) (13)
Medical and Obstetric Complications Among Pregnant Women With Liver Cirrhosis. (2017) (13)
Liver biopsy in living donors (2002) (12)
Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis. (2020) (12)
Intensive management of hepatic failure. (2006) (12)
Resting and Exercise Energy Metabolism After Liver Transplantation for Nonalcoholic Steatohepatitis (2017) (11)
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. (2022) (11)
Preparing for the NASH Epidemic: A Call to Action (2021) (10)
Twenty‐five‐year trajectories of insulin resistance and pancreatic β‐cell response and diabetes risk in nonalcoholic fatty liver disease (2018) (10)
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach (2021) (9)
NAFLD and Cardiovascular Disease: Can the Real Association Be Determined? (2014) (8)
Amelioration of hepatic inflammation in a mouse model of NASH using a dithiocarbamate derivative (2013) (8)
Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges (2019) (8)
Fatty Liver Disease: Diagnosis and Stratification. (2021) (8)
Moderate Exercise for Nonalcoholic Fatty Liver Disease. (2016) (7)
Associating Serenoa Repens, Urtica Dioica and Pinus Pinaster. Safety and Efficacy in the Treatment of Lower Urinary Tract Symptoms. Prospective Study on 320 Patients (2010) (7)
932 Pentoxifylline Improves Non-Invasive Serum Markers of Fibrosis: Combined Results From 2 Randomized, Placebo-Controlled Trials (2012) (6)
OTU-14 Positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH (2019) (6)
938 Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH (2019) (5)
Screening for nonalcoholic fatty liver disease in patients with atherosclerotic coronary disease?—In principle yes, in practice not yet (2016) (5)
Factors impacting survival in those transplanted for NASH cirrhosis: Data from the NailNASH Consortium. (2022) (5)
Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? (2017) (5)
Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C. (2010) (4)
Editorial: sarcopenia in liver transplantation—our weakest patients may need the strongest push (2019) (4)
Obeticholic acid treatment in patients with non-alcoholic steatohepatitis: a secondary analysis of the REGENERATE study across fibrosis stages (2020) (4)
Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients. (2019) (3)
Complications during pregnancy in the liver transplant patient (2006) (3)
EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a argon-1 study (2020) (3)
The “dose” of exercise and its effects beyond weight loss (2015) (3)
334 OBETICHOLIC ACID IMPROVES EXPERIMENTAL NON-INVASIVE MARKERS OF NON-ALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS; RESULTS OF A SECONDARY ANALYSIS FROM THE MONTH-18 INTERIM ANALYSIS OF THE REGENERATE STUDY (2020) (2)
Higher early post-liver transplant mortality in recipients with severe alcoholic hepatitis versus alcoholic cirrhosis (2018) (2)
Obeticholic acid improves experimental non-invasive markers of non-alcoholic steatohepatitis and advanced fibrosis: a secondary analysis of the phase 3 regenerate study (2020) (2)
Evaluation of SOMAscan as a discovery platform to identify noninvasive protein biomarkers for diagnosis and monitoring of NASH (2018) (2)
Treatment with selonsertib, an inhibitor of apoptosis signal-regulating kinase 1, hepatic phospho-p38 expression and markers of hepatocellular apoptosis and necrosis in patients with nonalcoholic steatohepatitis (2017) (2)
Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 vs. placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: a phase 2 randomised controlled trial (FASCINATE-1) (2020) (2)
Pregnancy Outcomes Among Women With Liver Cirrhosis [8OP] (2017) (2)
Preparing for the NASH epidemic: A call to action (2021) (2)
Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey (2022) (2)
925 Early Cardiovascular Disease Mortality After Liver Transplantation—Is Nonalcoholic Steatohepatitis (NASH) to Blame? (2014) (2)
13C-methacetin breath test is a highly accurate non-invasive point of care test for detecting CSPH in patients with NASH (2018) (1)
Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients (2021) (1)
A217 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL (2021) (1)
Pregnancy Primary biliary cirrhosis (2006) (1)
Transcriptional Regulation of Murine Slc 22 a 11 ( Oct 1 ) by Peroxisome-proliferator agonist receptor ( PPAR )-alpha and-gamma (2004) (1)
2111 (2017) (1)
PC.01.9 EVALUATION OF OBETICHOLIC ACID EFFICACY IN PATIENTS WITH NASH WHO WERE MONITORED USING NONINVASIVE TESTS: A POST HOC ANALYSIS OF THE REGENERATE TRIAL (2021) (1)
703 TTR-ABCB11 transgenic mice fed a high fat diet are obese, insulin resistant and develop hepatic steatosis (2003) (1)
Thanks to CLD for Small Favors: Reduced CVD Risk in Patients Awaiting Liver Transplantation (2020) (1)
P213 Obeticholic acid improves hepatic fibroinflammation assessed by multiparametric MRI: interim results of the regenerate trial (2020) (1)
Tu1665 OBETICHOLIC ACID IMPROVES HEPATIC FIBROINFLAMMATION AS ASSESSED BY MULTIPARAMETRIC MRI: INTERIM RESULTS OF THE REGENERATE TRIAL (2020) (1)
Association of nonalcoholic fatty liver disease with changes in left ventricular structure and function: The coronary artery risk development in young adults (CARDIA) study (2018) (1)
PATTERNS OF ALCOHOL USE AFTER EARLY LIVER TRANSPLANTATION (LT) FOR ALCOHOLIC HEPATITIS (AH): IMPLICATIONS FOR SELECTION AND MONITORING (2019) (1)
Authors' response. (2013) (0)
Prebiotic activity of lactulose optimizes gut metabolites and prevents systemic infection in liver disease patients (2023) (0)
2111: Insulin resistance patterns over 25-years of adulthood and nonalcoholic fatty liver disease in middle age: The Coronary Artery Risk Development in Young Adults (CARDIA) Study (2017) (0)
Long-term associations between non-high density Lipoprotein Cholesterol and Apolipoprotein B in young adulthood and subclinical atherosclerosis in persons with nonalcoholic fatty liver disease in middle age: the CARDIA study (2018) (0)
Assessing the applicability of non-invasive diagnostic tests (NITs) in non-alcoholic fatty liver disease: an international qualitative study (2022) (0)
Abstract 05: Association of 25-Year Body Mass Index Trajectories Throughout Early Adulthood With Nonalcoholic Fatty Liver Disease in Middle Age: The Coronary Artery Risk Development in Young Adults (CARDIA) Study (2017) (0)
LESS ISMORE Moderate Exercise for Nonalcoholic Fatty Liver Disease (2016) (0)
Paper alert. (2020) (0)
GFR reset point at 3 months after liver transplant is a superior predictor of liver and kidney disease related outcomes: analysis from a large cohort of NASH patients (nail NASH consortium) (2020) (0)
Nonalcoholic Fatty Liver Disease and Steatohepatitis (2016) (0)
Research Priorities for Precision Medicine in NAFLD. (2023) (0)
Maternal and pregnancy outcomes in women with cirrhosis: room for optimizing care (2017) (0)
361 Early Liver Transplantation in Severe Alcoholic Hepatitis: A Multi-Center, Retrospective, Cohort Study (2015) (0)
Mo1448 OBETICHOLIC ACID IMPROVES TRANSAMINASES IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE 18-MONTH INTERIM ANALYSIS OF THE REGENERATE STUDY (2020) (0)
Transcriptional regulation of murine Slc22a1 (Oct1) by peroxisome proliferator agonist receptor- (cid:1) and - (cid:2) (2004) (0)
Obeticholic acid (OCA) improves non-invasive markers of fibrosis in patients with non-alcoholic steatohepatitis (NASH): a secondary analysis of the phase 3 Regenerate study (2020) (0)
Incidence and risk factors for cardiovascular events in patients with advanced fibrosis due to non-alcoholic steatohepatitis: data from the phase 3 STELLAR trials (2020) (0)
AF.81 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL (2021) (0)
Drug-induced Liver Injury Associated with the Glucagon-like Peptide 1 (GLP-1) Agonist Liraglutide: 1131 (2013) (0)
Utility of metabolomic biomarkers to identify non-alcoholic fatty liver disease in liver transplant recipients (2020) (0)
Treatment Targets and Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH): A Summary of AALSD Trend Conference in NASH (2020) (0)
Association between history of bariatric surgery and graft rejection among solid organ transplant recipients (2020) (0)
T06.01.12 OBETICHOLIC ACID (OCA) IMPROVES NON-INVASIVE MARKERS OF FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH): A SECONDARY ANALYSIS OF THE PHASE 3 REGENERATE STUDY (2020) (0)
PS-206-Patterns and predictors of alcohol use after early liver transplant for alcoholic hepatitis (2019) (0)
PGI49 - HUMANISTIC BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) – IN THE FIRST REAL-WORLD CROSS-SECTIONAL STUDY, SYMPTOMATIC NASH PATIENTS REPORT WORSE QUALITY OF LIFE (2018) (0)
Table of contents (2016) (0)
Editorial: global liver fat accumulation and global health—towards a sustainable development goal. Authors' reply (2022) (0)
Effects of liver transplantation on cardiac function in patients transplanted for NASH cirrhosis (2017) (0)
An algorithm for the management of non-alcoholic fatty liver disease in primary care (2021) (0)
A219 AMINOTRANSFERASE IMPROVEMENTS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS ARE ASSOCIATED WITH FIBROSIS REGRESSION IN THE REGENERATE STUDY (2022) (0)
Mo1484 ADHERENCE TO ESTABLISHED PROCESS MEASURES IN THE EVALUATION OF HEPATIC STEATOSIS ON IMAGING AT A LARGE TERTIARY CARE HOSPITAL (2020) (0)
Obeticholic acid demonstrates sustained improvements at month 24 in transaminases and non-invasive markers of fibrosis: Results of a post hoc analysis from the interim analysis of the REGENERATE study (2020) (0)
Environmental Risk Factors in Superficial Bladder Cancer (2004) (0)
Long-term outcome of patients undergoing OLT for hepatitis B-related liver disease without HBIG prophylaxia (1998) (0)
O26 Obeticholic acid improves experimental noninvasive markers of nonalcoholic steatohepatitis and advanced fibrosis: results from regenerate (2021) (0)
326 OBESITY-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE REGENERATE STUDY (2020) (0)
Mechanisms of NAFLD development and therapeutic strategies (2018) (0)
Osservational Study on Early Diagnosis of Prostate Carcinoma in Sicily and Calabria (2004) (0)
What Are the Best Diagnostic Modalities for Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis and Associated Fibrosis? A Summary of AALSD Trend Conference in NASH (154/120) (2020) (0)
Obeticholic acid (OCA) improves experimental non-invasive markers of NASH and advanced fibrosis: results of a secondary analysis from the month-18 interim analysis of the REGENERATE study (2020) (0)
Recurrent NAFLD post LT: sisyphus' boulder or proteus' parable? (2023) (0)
Mo1456 UTILITY OF METABOLOMIC BIOMARKERS TO IDENTIFY NONALCOHOLIC FATTY LIVER DISEASE IN LIVER TRANSPLANT RECIPIENTS (2020) (0)
Abstract 20341: Determinants of Abnormal Cardiac Mechanics in Liver Transplant Candidates With Hepatic Steatosis (2014) (0)
Re-establishing abstinence after alcohol relapse after early transplant (LT) for alcoholic hepatitis (AH) provides survival advantage (2020) (0)
S3243 A Budding Dilemma: A Rare Case of Sickle Cell Disease Causing Incidental Budd-Chiari Syndrome (2022) (0)
Table of contents (2016) (0)
Primary biliary cirrhosis. (2006) (0)
PGI52 - DECREASED WORK PRODUCTIVITY AND INCREASED HEALTHCARE RESOURCE UTILISATION (HRU) AMONG PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) – RESULTS FROM A REAL WORLD EVIDENCE STUDY (2018) (0)
Adherence to established process measures in the evaluation of hepatic steatosis on imaging in a large tertiary care network (2020) (0)
The Management of Pregnancy in Patients with Advanced Liver Disease Before and After Liver Transplantation (2016) (0)
The Cost of Diagnosing and Managing Non-alcoholic Steatohepatitis in Europe and the United States. (2022) (0)
Liver Disease LIVER DISEASE IN PREGNANCY (0)
O57 EARLY CARDIOVASCULAR DISEASE MORTALITY AFTER LIVER TRANSPLANTATION – IS NONALCOHOLIC STEATOHEPATITIS (NASH) TO BLAME? (2014) (0)
Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Nonhepatocellular Cancers. (2023) (0)
The journey of a patient with biopsy-proven non-alcoholic steatohepatitis (NASH) – results from a real-world study (2019) (0)
Should Liver Biopsy Be Performed in All Patients With Nonalcoholic Fatty Liver Disease (2011) (0)
Iconography : The Role of Diet and Nutrient Composition in Nonalcoholic Fatty Liver Disease (2012) (0)
Screening for non-alcoholic fatty liver disease in persons with type 2 diabetes in the U.S. is cost effective: A comprehensive economical analysis (2020) (0)
Obesity-specific health-related quality of life in patients with non-alcoholic steatohepatitis: results from the regenerate study (2020) (0)
Obeticholic Acid Efficacy in Patients With NASH Monitored Using Noninvasive Tests: Post Hoc Analysis of REGENERATE Trial (2021) (0)
HMG-COA REDUCTASE INHIBITORS (STATINS) AND METFORMIN ARE ASSOCIATED WITH PRESERVATION OF HEPATIC FUNCTION AND LESS PORTAL-SYSTEMIC SHUNTING IN ADVANCED CHRONIC LIVER DISEASE (2021) (0)
Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric magnetic resonance imaging: interim results of the regenerate trial (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Mary Eugenia Rinella?

Mary Eugenia Rinella is affiliated with the following schools:

Northwestern University